Register entry
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
- Registered sites
- 0
- Active NDC listings
- 0
- Live patents
- 22
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
22| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 10682376 | VELPHOROferric oxyhydroxide | product | Nov 2028 |
| 10695367 | VELPHOROferric oxyhydroxide | product | Nov 2028 |
| 10925896 | VELPHOROferric oxyhydroxide | product | Nov 2028 |
| 10925897 | VELPHOROferric oxyhydroxide | product | Nov 2028 |
| 10933090 | VELPHOROferric oxyhydroxide | product | Nov 2028 |
| 11013761 | VELPHOROferric oxyhydroxide | product | Nov 2028 |
| 11013762 | VELPHOROferric oxyhydroxide | product | Nov 2028 |
| 10682376*PED | VELPHOROferric oxyhydroxide | use | May 2029 |
| 10695367*PED | VELPHOROferric oxyhydroxide | use | May 2029 |
| 10925896*PED | VELPHOROferric oxyhydroxide | use | May 2029 |
| 10925897*PED | VELPHOROferric oxyhydroxide | use | May 2029 |
| 10933090*PED | VELPHOROferric oxyhydroxide | use | May 2029 |
| 11013761*PED | VELPHOROferric oxyhydroxide | use | May 2029 |
| 11013762*PED | VELPHOROferric oxyhydroxide | use | May 2029 |
| 9561251 | VELPHOROferric oxyhydroxide | product | Jan 2030 |
| 9561251*PED | VELPHOROferric oxyhydroxide | use | Jul 2030 |
| 10624855 | VELPHOROferric oxyhydroxide | product | Nov 2034 |
| 11234938 | VELPHOROferric oxyhydroxide | product | Nov 2034 |
| 11446252 | VELPHOROferric oxyhydroxide | product | Nov 2034 |
| 10624855*PED | VELPHOROferric oxyhydroxide | use | May 2035 |
| 11234938*PED | VELPHOROferric oxyhydroxide | use | May 2035 |
| 11446252*PED | VELPHOROferric oxyhydroxide | use | May 2035 |
| Product | Exclusivity | Until |
|---|---|---|
| VELPHOROFERRIC OXYHYDROXIDE | PED Paediatric | Jan 2028 |
Enquiry
Common questions
- Is VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE FDA approved?
- VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE holds no registered establishment of its own; it appears here on its Orange Book patents.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.